Quintessence Biosciences, Inc.

Madison, WI 53719

SBIR Award Summary

Total Number of Awards 5
Total Value of Awards $1.4MM
First Award Date 05/15/06
Most Recent Award Date 09/01/10

Key Personnel

Last Name Name Awards Contact
Trubetskoy Vladimir S Trubetskoy 1
Shahan Mark N Shahan 3
Strong Laura E Strong 1

5 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-08-050
Budget: 09/01/10 - 08/31/11

DESCRIPTION (provided by applicant): The ultimate goal of this project is to develop a new safe AND effective tool for physicians to treat patients with cancer. The EVade Ribonucleases are recombinant variants of mammalian enzymes that are effective in mouse xenograft models of multiple cancer types without exhibiting significant toxicity. While...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-08-050
Budget: 09/01/09 - 08/31/10

DESCRIPTION (provided by applicant): The ultimate goal of this project is to develop a new safe AND effective tool for physicians to treat patients with cancer. The EVade Ribonucleases are recombinant variants of mammalian enzymes that are effective in mouse xenograft models of multiple cancer types without exhibiting significant toxicity. While...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-20
Budget: 09/28/07 - 09/27/08

DESCRIPTION (provided by applicant): The goal of this project is to develop a safe yet potent antibody-drug conjugate (ADC) by utilizing an EVade(tm) Ribonuclease as the drug. The EVade(tm) Ribonucleases are variants of mammalian enzymes that are effective in mouse xenograft models of multiple cancer types without exhibiting significant toxicit...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-20
Budget: 07/27/07 - 06/30/08

DESCRIPTION (provided by applicant): 6. Project Summary Abstract The goal of this project is to develop a safe yet potent drug utilizing an EVade(tm) Ribonuclease. The EVade(tm) Ribonucleases are recombinant variants of mammalian enzymes that are effective in mouse xenograft models of multiple cancer types without exhibiting significant toxicity...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 05/15/06 - 05/31/07

DESCRIPTION (provided by applicant): Development of technologies enabling early drug absorption profiling for novel drug candidates is one of the crucial issues facing modern drug discovery research. Current approaches are low-throughput and suffer from difficulties with poor reproducibility and poor compatibility with existing instrumentation. ...